Abstract
Background Transplant practices related to use of organs from hepatitis C virus-infected donors (DHCV+) is evolving rapidly. Methods We surveyed US kidney transplant programs by email and professional society LISTSERV postings between July 2019 and January 2020 to assess attitudes, management strategies, and barriers related to use of viremic (nucleic acid testing positive [NAT+]) donor organs in recipients who are not infected with HCV. Results Staff at 112 unique programs responded, representing 54% of US adult kidney transplant programs and 69% of adult deceased donor kidney transplant volume in 2019. Most survey respondents were transplant nephrologists (46%) or surgeons (43%). Among the responding programs, 67% currently transplant DHCV antibody+/NAT- organs under a clinical protocol or as standard of care. By comparison, only 58% offer DHCV NAT+ kidney transplant to recipients who are HCV-, including 35% under clinical protocols, 14% as standard of care, and 9% under research protocols. After transplant of DHCV NAT+ organs to recipients who are uninfected, 53% start direct-acting antiviral agent (DAA) therapy after discharge and documented viremia. Viral monitoring protocols after DHCV NAT+ to HCV uninfected recipient kidney transplantation varied substantially. 56% of programs performing these transplants report having an institutional plan to provide DAA treatment if declined by the recipient's insurance. Respondents felt a mean decrease in waiting time of ≥18 months (range, 0-60) justifies the practice. Program concerns related to use of DHCV NAT+ kidneys include insurance coverage concerns (72%), cost (60%), and perceived risk of transmitting resistant infection (44%). Conclusions Addressing knowledge about safety and logistic/financial barriers related to use of DHCV NAT+ kidney transplantation for recipients who are not infected with HCV may help reduce discards and expand the organ supply.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1291-1299 |
| Number of pages | 9 |
| Journal | Kidney360 |
| Volume | 1 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 1 2020 |
Funding
K. Lentine serves on the American Society of Nephrology (ASN) Quality Committee and reports personal consulting fees from CareDx and speaker honoraria from Sanofi, outside the submitted work. J. Peipert reports grants from Veloxis, outside the submitted work. R. Forbes reports personal fees from OrthoDiagnostics and Veloxis, outside the submitted work. Schntizler reports personal consulting fees from CareDx, outside the submitted work. R. Bloom reports reports being an advisor to Merck (2017–2018) and to Abbvie (2017–2018). R. Mannon serves on the ASN Policy Committee; reports grants from Malilinckrodt and Transplant Genomics; personal fees from Hansa, Novartis, Sanofi, and Vitaeris; and grants from Quark, outside the submitted work. D. Axelrod reports personal consulting fees from CareDx and perosnal advisory board fees from Veloxis and Sanofi, outside the submitted work. All remaining authors have nothing to disclose.
Keywords
- direct acting antiviral therapy
- donation
- hepatitis C virus
- infection
- kidney transplantation
- practices
- surveys and questionnaires
- tissue donors
- transplantation
ASJC Scopus subject areas
- Nephrology
- Medicine (miscellaneous)
